DiagnosticsTechnology

Amnestix Develops Genetic Analysis System

1 Mins read

Amnestix is a biopharmaceutical company that has developed a powerful analytical platform to identify genetic determinants that underlie neurological disorders. The company’s genetic analysis system is called whole-genome association, and functions by comparing the genome of healthy and ill patients at hundreds of thousands of positions in order to identify where disease-prone genomes differ from healthy genomes. The company has used its technology to identify a bioactive protein essential for memory function, termed KIBRA.

Amnestix is a biopharmaceutical company that has developed a powerful analytical platform to identify genetic determinants that underlie neurological disorders. The company’s genetic analysis system is called whole-genome association, and functions by comparing the genome of healthy and ill patients at hundreds of thousands of positions in order to identify where disease-prone genomes differ from healthy genomes. The company has used its technology to identify a bioactive protein essential for memory function, termed KIBRA. The company is currently developing therapeutics targeting KIBRA which are indicated to treat acute memory loss, as seen in Alzheimer’s disease. The company’s analytical platform is currently being used to study other neurological disorders, including schizophrenia.

 

Related posts
DiagnosticsTechnology

New Medical Laboratories Are the Key to Diagnostics Research

3 Mins read
The development of the COVID-19 vaccine was a miracle in medical research. It shows the incredible importance of medical innovation in the…
DiagnosticsTechnology

How Rapid Blood Testing Solves Blood Lab Wait Time Issues

3 Mins read
In early November 2020, Steven Hill* experienced a concerning and prolonged bout of nausea, weakness, and a host of other symptoms that…
Health careMedical DevicesTechnology

Can Medical Devices Help Reduce the Cost of Healthcare?

8 Mins read
Healthcare costs are on the rise; according to CNN Money, a 2016 report reveals the huge cost gap between the early 2000s…